The Biosimilars and Follow-on Biologics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand of Drugs For Treating Chronic Conditions

The increasing demand for drugs stems from their remarkable efficacy in treating a wide array of chronic and complex diseases, ranging from cancer to autoimmune disorders and beyond. Chronic conditions such as diabetes, rheumatoid arthritis, and various forms of cancer are becoming increasingly prevalent, driving up the need for effective long-term treatments. This surge is propelled by various factors, including the aging population, the prevalence of lifestyle-related ailments, and advancements in medical science enabling earlier detection and prolonged treatment.

As our understanding of disease mechanisms deepens, biologics continue to be at the forefront of medical innovation, offering hope for patients with previously untreatable conditions. Additionally, heightened awareness and evolving healthcare policies advocating proactive management of chronic illnesses further contribute to the increasing demand for these drugs.

Favourable regulatory policies for approval of biosimilars

Regulatory agencies around the world have recognized the importance of establishing clear and transparent pathways for the approval of biosimilars, ensuring that these products meet stringent standards of quality, safety, and efficacy.

One of the key elements of favourable regulatory policies is the establishment of specific guidelines and frameworks tailored to the unique characteristics of biosimilars. Unlike small molecule drugs, which can be replicated with relative ease, biologics are large, complex molecules produced in living cells, making their development and characterization more challenging. Regulatory pathways allow biosimilar manufacturers to rely on existing clinical data for reference biologics, expediting the approval process while still requiring robust comparative analytical and clinical studies to demonstrate similarity and safety. By providing clear expectations and requirements, these guidelines enable manufacturers to navigate the regulatory process more efficiently and effectively, accelerating the development and approval of biosimilars.

Moreover, favourable regulatory policies include provisions to expedite the review and approval of biosimilar products, fostering competition and expanding patient access to affordable treatments. Regulatory agencies may employ mechanisms such as abbreviated pathways or priority review designations to streamline the approval process for biosimilars, particularly for products targeting diseases with significant unmet medical needs. These expedited pathways help bring biosimilar products to market more quickly, encouraging innovation and investment in the biosimilars space.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Biosimilars and Follow-on Biologics Market evolving?
  • What is driving and restraining the Biosimilars and Follow-on Biologics Market?
  • How will each Biosimilars and Follow-on Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each Biosimilars and Follow-on Biologics submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading Biosimilars and Follow-on Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Biosimilars and Follow-on Biologics projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of Biosimilars and
  • Follow-on Biologics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Biosimilars and Follow-on Biologics Market?
  • Where is the Biosimilars and Follow-on Biologics Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biosimilars and Follow-on Biologics market today, and over the next 10 years:

  • Our 391-page report provides 156 tables and 200 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Biosimilars and Follow-on Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Biosimilars and Follow-on Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product Type

  • Recombinant Non-Glycosylated Proteins
    – Human Growth Hormone
    – Granulocyte Colony-Stimulating Factor (Filgrastim)
    – Insulin
    – Interferon
  • Recombinant Glycosylated Proteins
    – Erythropoietin
    – Monoclonal Antibodies (Infliximab, Rituximab, Adalimumab, Trastuzumab, Bevacizumab, Etanercept)
    – Follitropin
    – Low Molecular Weight Heparin


  • Hematology
    – Neutropenia
    – Anemia
    – Others
  • Oncology
    – Lung Cancer
    – Brain Cancer
    – Breast Cancer
    – Cervical Cancer
    – Colorectal Cancer
    – Leukemia
    – Others
  • Autoimmune Disease
    – Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Others)
    – Inflammatory Bowel Disease (Ulcerative Colitis, Crohn’s Diseases, Others)
    – Psoriasis
    – Others
  • Growth Hormone Deficiency
  • Diabetes
  • Others


  • Recombinant DNA (rDNA) Technology
  • Monoclonal Antibodies (MAb) Technology


  • Contract Research and Manufacturing Services
  • In-house

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 27 leading national markets:

North America

  • U.S.
  • Canada


  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Poland
  • Belgium
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Taiwan
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America


  • GCC
  • South Africa
  • Rest of MEA